Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.
Company profile
Ticker
APGE
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Apogee Therapeutics, LLC
SEC CIK
Corporate docs
IRS number
880588063
APGE stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Regulation FD Disclosure
25 Mar 24
424B4
Prospectus supplement with pricing info
11 Mar 24
EFFECT
Notice of effectiveness
8 Mar 24
S-1MEF
Registration of additional securities for an S-1
7 Mar 24
S-1
IPO registration
5 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
Latest ownership filings
4
Peter Evan Harwin
1 Apr 24
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Peter Evan Harwin
31 Jan 24
SC 13D/A
Fairmount Funds Management LLC
31 Jan 24
4
Carl Dambkowski
20 Dec 23
4
Jane Henderson
20 Dec 23
4
MICHAEL THOMAS HENDERSON
20 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 188.27 mm | 188.27 mm | ||||
Cash burn (monthly) | (no burn) | 8.10 mm | ||||
Cash used (since last report) | n/a | 56.05 mm | ||||
Cash remaining | n/a | 132.22 mm | ||||
Runway (months of cash) | n/a | 16.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 73 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 848.05 bn |
Total shares | 43.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
VR Adviser | 8.49 mm | $180.91 bn |
FMR | 4.44 mm | $89.62 bn |
Venrock Healthcare Capital Partners III | 3.89 mm | $80.47 mm |
Fairmount Funds Management | 2.94 mm | $62.65 bn |
Deep Track Capital | 2.41 mm | $51.43 bn |
RTW Investments | 2.14 mm | $45.64 bn |
Ra Capital Management | 1.98 mm | $42.13 bn |
Perceptive Advisors | 1.83 mm | $38.93 bn |
BLK Blackrock | 1.66 mm | $35.39 bn |
Wellington Management | 1.59 mm | $33.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Fairmount Funds Management | Common Stock | Other | Acquire J | Yes | No | 0 | 55,913 | 0.00 | 2,048,647 |
28 Mar 24 | Fairmount Funds Management | Common Stock | Other | Dispose J | Yes | No | 0 | 55,913 | 0.00 | 0 |
28 Mar 24 | Fairmount Funds Management | Non-Voting Common Stock Common Stock | Other | Acquire J | Yes | No | 0 | 221,426 | 0.00 | 6,743,321 |
28 Mar 24 | Fairmount Funds Management | Non-Voting Common Stock Common Stock | Other | Dispose J | Yes | No | 0 | 221,426 | 0.00 | 0 |
29 Jan 24 | Fairmount Funds Management | Common Stock | Other | Acquire J | Yes | Yes | 0 | 51,166 | 0.00 | 51,166 |
29 Jan 24 | Fairmount Funds Management | Common Stock | Other | Acquire J | Yes | Yes | 0 | 51,166 | 0.00 | 51,166 |
29 Jan 24 | Fairmount Funds Management | Common Stock | Other | Dispose J | Yes | Yes | 0 | 892,529 | 0.00 | 0 |
18 Dec 23 | Michael Thomas Henderson | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 398,512 | 9.11 mm | 398,512 |
18 Dec 23 | Henderson Jane | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 175,345 | 4.01 mm | 175,345 |
18 Dec 23 | Carl Dambkowski | Stock Option Common Stock | Grant | Acquire A | No | No | 22.86 | 175,345 | 4.01 mm | 175,345 |
News
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
14 Mar 24
Reported Earlier, Apogee Therapeutics Prices Upsized $420M Underwritten Public Offering Of 6,774,193 Common Shares At $62/Share
8 Mar 24
Jefferies Maintains Buy on Apogee Therapeutics, Raises Price Target to $75
6 Mar 24
Apogee Therapeutics Announces Commencement Of $350M Proposed Underwritten Public Offering
5 Mar 24
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
5 Mar 24
Press releases
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
25 Mar 24
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million
12 Mar 24
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
7 Mar 24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
5 Mar 24